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Oxidative stress is implicated as a major factor in the development of diabetes complications and is caused in part by
advanced glycation end products (AGEs). AGEs ligate to the receptor for AGEs (RAGE), promoting protein kinase C (PKC)-
dependent activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and superoxide radical generation.
While scavenging antioxidants are protective against AGEs, it is unknown if induction of endogenous antioxidant defenses has the
same eﬀect. In this study, we conﬁrmed that the compound 3H-1,2-dithiole-3-thione (D3T) increases reduced-state glutathione
(GSH) concentrations and NADPH:quinone oxidoreductase 1 (NQO1) activity in SH-SY5Y cells and provides protection against
H2O2. Surprisingly, D3T potentiated oxidative damage caused by AGEs. In comparison to vehicle controls, D3T caused greater
AGE-induced cytotoxicity and depletion of intracellular GSH levels while oﬀering no protection against neurite degeneration or
protein carbonylation. D3T potentiated AGE-induced reactive oxygen species (ROS) formation, an eﬀect abrogated by inhibitors
of PKC and NADPH oxidase. This study suggests that chemical induction of endogenous antioxidant defenses requires further
examination in models of diabetes.
1.Introduction
Oxidative stress is a primary component of diabetes pathol-
ogy [1] and is considered a causal factor for the development
of complications like neuropathy [2], which is characterized
by hyperalgesia and sensory dysfunction [3–5]. Antioxidants
suppress oxidative stress and ameliorate symptoms of dia-
betic neuropathy in experimental systems [6, 7], and while
antioxidants have the potential to provide clinical beneﬁt
[8], more studies are required to properly investigate the
eﬀectiveness of antioxidants in humans.
Concentrations of reactive oxygen species (ROS) are ele-
vated in diabetes due to increased mitochondrial superoxide
radical generation and depletion of endogenous antioxidant
systems [9–11]. ROS are also the result of advanced gly-
cation end products (AGEs), which are produced by the
nonenzymatic glycation of proteins [12, 13]. Carboxymethyl
lysine (CML)—a regularly formed product of protein
glycation [14]—ligates to the receptor for AGEs (RAGE)
[15], facilitating activation of extracellular signal-regulated
kinase (ERK) [16], p38 kinase [17], and the transcription
factor NF-kappaB [17]. In neuronal cells, RAGE ligation
increases protein kinase C (PKC)-dependent nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase activity
and superoxide radical generation [18, 19]. This pathway
of ROS generation causes apoptosis and macromolecule
damage in vitro [19, 20]a sw e l la sf u n c t i o n a ln e u r o l o g i c a l
deﬁcits in vivo [21–23].
Antioxidants such as probucol [23], α-tocopherol [24],
α-lipoic acid [25], and N-acetyl-cysteine (NAC) [23, 25,
26] provide cytoprotection against AGEs. NAC exerts its
protective eﬀects by increasing intracellular GSH [27, 28];
studying alternative methods of increasing intracellular GSH
might highlight additional mechanisms that protect neurons2 Experimental Diabetes Research
fromAGE-induceddamage.Onesuchmechanismisthrough
activation of the transcription factorNrf2, which is responsi-
bleforconstitutiveandinducibleupregulationofantioxidant
enzymes, including those responsible for GSH regulation.
Nrf2 activity can be stimulated by chemical compounds
from the diet, including dithiolethiones, which are sulfur-
containing compounds found in cruciferous vegetables.
One of the dithiolethiones, 3H-1,2-dithiole-3-thione (D3T),
potently upregulates antioxidant genes in cells and in vivo
[28, 29] by activating Nrf2 [30]. Because D3T-mediated
protection involves increased GSH biosynthesis [28], we
hypothesized that D3T would confer protection against
AGE-induced oxidative stress.
In this paper, we used SH-SY5Y cells to conﬁrm previous
reports that D3T increases intracellular GSH levels as well
as activity of the antioxidant enzyme NADPH:quinone
oxidoreductase 1 (NQO1). We report that D3T pretreatment
partially suppressed H2O2-induced cytotoxicity. However,
D3T potentiated harmful eﬀects of AGEs. D3T pretreatment
caused greater AGE-induced cytotoxicity and GSH deple-
tion, and it had no eﬀect on protein carbonylation and
neurite degeneration. We found that D3T caused higher
r a t e so fA G E - i n d u c e dR O Sf o r m a t i o n ,a ne ﬀect suppressed
by inhibitors of PKC and NADPH oxidase. In all, D3T
potentiates the toxic eﬀects of AGEs in a cell culture model
of diabetic neuropathy.
2.MaterialsandMethods
2.1. Materials. Cell culture supplies, including Dulbecco’s
modiﬁed Eagle’s medium (DMEM), Ham’s F12 media,
fetal bovine serum (FBS), and penicillin-streptomycin, were
obtained from Invitrogen (Carlsbad, CA, USA). Materials
for AGE-BSA formation, including fatty acid-free BSA
and glycolaldehyde, were obtained from Sigma-Aldrich
(St. Louis, MO, USA). Retinoic acid (RA) and dimethyl
sulfoxide (DMSO) were also purchased from Sigma-Aldrich.
All cultureware was obtained from VWR (West Chester,
PA, USA). SH-SY5Y cells were purchased from ATCC
(Manassas, VA, USA). N-acetyl-cysteine (NAC) and α-
tocopherol were obtained from Sigma-Aldrich. 3H-1,2-
dithiole-3-thione (D3T) was purchased from LKT Labora-
tories (St. Paul, MN, USA).
2.2. Formation of AGE-BSA. AGE-BSA was prepared as
described previously [31] with minor alterations. Brieﬂy,
BSA (5mg/mL in PBS) was incubated with 33mM gly-
colaldehyde dimer for 20 hours at 37◦C. Glycated BSA
was then dialyzed extensively for several days against PBS
at 4◦C. To concentrate the proteins to achieve high-dose
treatments, AGE-BSA was precipitated using ammonium
sulfate (Mallinckrodt Chemicals, Phillipsburg, NJ, USA).
The protein precipitate was then reconstituted in a smaller
volume of PBS and dialyzed again for several days against
PBS at 4◦C. Control (unglycated) BSA was treated the
same except that the initial incubation was in PBS without
glycolaldehyde. After the second dialyzing step, protein
concentrations were quantiﬁed using a BCA protein assay kit
(Pierce, Rockford, IL). Dilutions of 1mg/mL were then mea-
sured for absorbance at 340nm on a PowerWave plate reader
(BioTek Instruments, Winooski, VT, USA). Fluorescence
(335nm excitation, 420nm emission) was measured on a
SpectraMax Gemini XS ﬂuorescence plate reader (Molecular
Devices, Sunnyvale, CA, USA). Control BSA and AGE-BSA
stock solutions were aliquoted and frozen at −20◦C.
2.3. Cell Culture and Treatment. SH-SY5Y cells were grown
and maintained in 10% FBS and 1% penicillin-streptomycin
in DMEM at 37◦C and 7% CO2. For experiments, cells
were counted using Trypan Blue (ATCC) staining and seeded
in normal growth media. After allowing cells to adhere
overnight, neurite outgrowth was encouraged with 10μM
RA in DMEM:F12 (1:1) with 1% FBS for 3–5 days. For
experimentsusingD3T,cellswerepretreatedwitheitherD3T
or DMSO vehicle control (0.1% DMSO) for 24 hours in
DMEM:F12 (1:1) with 1% FBS and 10μM RA. After 24
hours, DMEM:F12 was removed and replaced with media
containing 4mg/mL BSA, AGE-BSA, or equivalent dilution
of PBS. Treatments lasted for 16–24 hours, and cells were
then harvested for speciﬁc experiments.
2.4. Cell Viability. Cell viability was assessed using the
MTT assay [32]. Our preliminary work with this assay
demonstrated that the changes in absorbance have high
correlation with SH-SY5Y cell number as determined by
trypan blue exclusion (R2 = 0.996). A stock solution
of 5mg/mL 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-
tetrazolium bromide (Sigma-Aldrich) in PBS was diluted
in media to 0.5mg/mL. After treatment, DMEM:F12 was
removed and cells were incubated for 3 hours with MTT
media. Purple formazan crystals that had formed in viable
cells were dissolved by adding 20% SDS (Sigma-Aldrich) in
50% dimethylformamide (Sigma-Aldrich) followed by agita-
tion on a plate shaker for one hour. Aliquots of 200μLw e r e
pipetted into a 96-well plate and read for a test absorbance
of 570nm and a background absorbance of 690nm on a
PowerWave plate reader (BioTek Instruments). Data were
expressed as percentage of PBS control. In experiments
involving D3T pretreatments, all values are expressed as
percentage of PBS control with DMSO pretreatment.
2.5. GSH Measurement. Total intracellular GSH was deter-
mined after cell treatments. Cells were washed three times
with PBS, scraped into ice-cold PBS, and centrifuged to
form a cell pellet. The pellet was resuspended in 5%
metaphosphoric acid + 100μM EDTA, and cells were lysed
byseveralfreeze-thawcycles.Acentrifugationsteppromoted
the precipitation of proteins that were later quantiﬁed using
aBCAproteinassaykit(Pierce).Thesupernatantwasﬁltered
and analyzed by high-performance liquid chromatogra-
phy (HPLC) with electrochemical detection. Speciﬁcally,
the samples were injected into an ESA Coularray system
(Chelmsford, MA, USA) with 5% mobile phase B (20%
methanol, 30% mobile phase A, 50% acetonitrile) in mobile
phase A (50mM sodium phosphate, pH 3). The predomi-
nant peak for GSH had a potential of 900mV and elutedExperimental Diabetes Research 3
at approximately 4.6 minutes. Samples were usually run the
day in which they were prepared; if this was not possible,
samples and standards were frozen at −80◦C until they could
be analyzed. GSH concentrations were normalized to total
protein.
2.6. NQO1 Activity. NQO1 activity was measured following
24 hours of D3T pretreatment by using a previously pub-
lished method [33] with some minor alterations. A quantity
of 7.0 × 105 cells was treated and washed twice with PBS
and incubated in 500μL 0.8% digitonin, 2mM EDTA, pH
7.8. The dishes were incubated for 10 minutes at 37◦Ca n d
then shaken on an orbital shaker. Aliquots of 50μL were then
used for analysis of NQO1 activity as indicated [33]. Similar
to the MTT assay, NQO1 activity depends on the reduction
of MTT to purple formazan crystals. NQO1 activity was
calculated based on change in absorbance over a speciﬁed
timeperiodandwith11,300M−1 cm−1 usedastheextinction
coeﬃcient for reduced MTT at 610nm. Additional aliquots
were used for quantiﬁcation of total protein by a Pierce BCA
total protein kit.
2.7.CellMorphology. SH-SY5Ycellswereplatedoncollagen-
coated cellware and treated with RA. Cells were then treated
for 24 hours with either 0.1% DMSO or 50μMD 3 T .D M S O
and D3T were removed and cells were treated with 4mg/mL
BSA, AGE-BSA, or an equivalent dilution with PBS for
an additional 24 hours. Some AGE-BSA-treated samples
also received 2.0mM NAC. The morphologies of cells were
documented using diﬀerential interference contrast (DIC)
microscopy on an Olympus 1 × 70 inverted microscope. An
Olympus DP70 digital camera system was used for image
capture at 10x, 20x, and 40x. Images were obtained from
at least four random ﬁelds in three independent samples
per treatment. Digital images at 40x were saved as random
numbers to allow for blinding, and neurites were counted
using Image J software (NIH).
2.8. Protein Carbonyls. SH-SY5Y cells were pretreated for 24
h o u r sw i t h0 . 1 %D M S Oo r5 0μM D3T and then treated for
24 hours with 4mg/mL BSA, AGE-BSA, or an equivalent
dilution with PBS. Cells were washed with ice-cold PBS three
times and then scraped into cold RIPA buﬀer containing
DTT. Centrifugation allowed for separation of insoluble pro-
tein components, and the concentration of soluble proteins
in RIPA buﬀer was quantiﬁed using the Pierce BCA protein
assaykit.SolubleproteinswerederivatizedusingtheOxyBlot
protein oxidation detection kit (Chemicon, Temecula, CA,
USA) according to the manufacturer’s instructions to detect
relative amounts of oxidized proteins. The derivatized pro-
teins were separated on a 12.5% Tris-HCl precast gel (Bio-
RadLaboratories,Hercules,CA,USA).Theoxidizedproteins
were detected by recommended antibody dilutions provided
withtheOxyBlotkitandwithuseofAmershamECLadvance
western blotting detection kit (GE Healthcare Life Sciences,
Buckinghamshire,UK).Theintensitiesofproteinbandswere
quantiﬁed by UN-SCAN-IT Gel 6.1 software (Silk Scientiﬁc,
Orem, UT, USA). The data were standardized and expressed
relative to PBS control with DMSO pretreatment.
2.9. Intracellular ROS Detection. To measure intracellular
H2O2 and hydroxyl radical concentrations, SH-SY5Y cells
were cultured in a 24-well plate and pretreated for 16 hours
with 0.1% DMSO or 50μMD3T followed by the addition of
2μM rottlerin or 20nMDPI for the 30 minutes immediately
prior to AGE-BSA or BSA treatment. BSA or AGE-BSA
(4mg/mL) was then added to each well. After 16 hours of
incubation, 5(6)-carboxy-2 ,7 -dichloroﬂuorescein diacetate
(DCFH) (Sigma-Aldrich) was added to wells for a ﬁnal
concentration of 50μM. Cells were incubated for 30 minutes
at 37◦C and then washed twice with DMEM containing
1% FBS. Prepared media (400μL) was added to each well,
and the ﬂuorescence was read by a SpectraMax Gemini
XS ﬂuorescence plate reader with an excitation wavelength
of 485nm and an emission wavelength of 530nm. A gain
in ﬂuorescence is indicative of DCFH oxidation [34]. The
background ﬂuorescence from empty wells was subtracted.
Results were standardized to cell density, and data were
e x p r e s s e da sap e r c e n to fP B Sc o n t r o lw i t hD M S Op r e t r e a t -
ment.
2.10. Statistical Analysis. All experiments were repeated
three times or more when speciﬁed. Statistical signiﬁcance
was determined by ANOVA. The Tukey test for multiple
comparisons of groups was performed as post hoc analysis.
Interactions with P values less than 0.05 were determined to
be statistically signiﬁcant.
3. Results
3.1. Inﬂuences of AGEs on Cell Viability. In this study, we
conﬁrmed previous ﬁndings that AGEs are cytotoxic to SH-
SY5Y cells [35, 36]. AGE-BSA (4mg/mL) decreased MTT
absorbance approximately 35% in comparison to PBS con-
trols (P<0.0001, data not shown); unglycated BSA caused
no negative eﬀects. We also conﬁrmed that the antioxidants
NAC and α-tocopherol partially suppressed AGE-induced
cell death (P<0.05 and P<0.0005 versus AGE-BSA,
resp.; data not shown). Using higher concentrations of AGE-
BSA than those in our previous studies did not alter our
ﬁndings that AGE-BSA—and not control BSA—decreases
cell viability, and antioxidants suppress this eﬀect.
3.2. Eﬀects of D3T on Antioxidant Defenses. We measured
intracellular GSH concentrations and NQO1 activity to test
the ability of D3T to upregulate endogenous antioxidant
defenses. D3T pretreatments equal to or below 10μM did
not aﬀect GSH concentrations, but 25μMD3T increased
intracellular GSH approximately 2.5-fold (P<0.001 versus
DMSO controls; data not shown) and 50μMD3T increased
GSH approximately 3.5-fold (P<0.0001 versus DMSO
controls). Treatment with 25–50μMD3T also increased
NQO1 activity. Because 25 and 50μMD3T increased mea-
sures of endogenous antioxidant defenses without negatively
impacting cell viability (data not shown), we proceeded with4 Experimental Diabetes Research
50μMD3T in follow-up studies. To conﬁrm whether upreg-
ulationofendogenousantioxidantdefensesbyD3Tincreases
stress resistance in our model, we pretreated SH-SY5Y cells
with either 0.1% DMSO or 50μMD3T for 24 hours and
followed this with 2 hours of incubation with 0, 200, or
500μMH 2O2 (data not shown). In vehicle controls, 200μM
H2O2 decreased viability approximately 40%, and 500μM
H2O2 decreased viability approximately 65% (P<0.0001
between 0, 200, and 500μMH 2O2). In comparison, D3T
increased cell viability approximately 20% in cells exposed
to H2O2 (P<0.0001 between D3T versus DMSO-pretreated
cells at each H2O2 concentration). Therefore, upregulation
of GSH and NQO1 activity by D3T protects SH-SY5Y cells
against H2O2. We then examined the ability of D3T pretreat-
menttoprotectagainstthemitochondriacomplexIinhibitor
rotenone. Rotenone caused an approximately 30% decrease
in viability as assessed by MTT assay; D3T had no eﬀect
on rotenone-induced cell death (data not shown). In all, we
conﬁrmedpreviousﬁndingsbyJiaetal.thatD3Tupregulates
GSH and NQO1 in SH-SY5Y cells and this protection
suppresses H2O2-induced cytotoxicity [37]. Although D3T
upregulates endogenous antioxidant defenses in SH-SY5Y
cells, our data suggest that the ability of D3T to promote
oxidative stress resistance depends on the speciﬁc stressor.
3.3. Inﬂuence of D3T on AGE-Induced Cell Loss. We pre-
treated SH-SY5Y cells with 0–50μMD 3 Ta n df o l l o w e dw i t h
24 hours of incubation with 4mg/mL BSA or AGE-BSA.
Both 25μMa n d5 0μM D3T increase endogenous antioxi-
dant defenses, but here 25μM D3T-pretreatment caused an
approximately 10% further decrease in viability after AGE-
BSA treatment. However, this interaction only approached
statistical signiﬁcance (P<0.10 versus 0.1% DMSO control
+ AGE-BSA). Surprisingly, 50μM D3T potentiated cytotox-
icity caused by AGE-BSA (Figure 1(a); P<0.0001 versus
DMSO); yet the same concentration caused no negative
impact on unglycated BSA-treated samples. Therefore, D3T
potentiates the cytotoxic eﬀects of AGE-BSA in a dose-
dependent manner and with a mechanism that appears to
be exclusive to this particular stress.
3.4. Eﬀects of AGE-BSA and D3T on GSH Levels and
Oxidative Damage. We tested whether D3T aﬀects AGE-
induced oxidative damage and GSH depletion. We observed
that BSA increased intracellular GSH compared to PBS
controls. We also noted that D3T pretreatment increased
G S Hw h e nc o m p a r e dt oD M S Oc o n t r o l s( P>0.01;
Figure 1(b)), except in AGE-BSA treated cells, where the
diﬀerence between DMSO and D3T pretreatments was
not statistically signiﬁcant. Thus, in comparison to vehicle
controls, D3T caused a larger AGE-induced decrease in GSH
(P>0.0001). In all, D3T increased intracellular GSH in
controls, but this antioxidant potentiated the decline in
GSH due to AGE-BSA, suggesting that D3T increases AGE-
induced oxidative stress.
InaneﬀorttoassesstheeﬀectsofD3Tonmacromolecule
oxidation, we examined protein carbonyl formation by
Oxyblot kit. Neither PBS nor BSA caused substantial protein
carbonylation in either DMSO or D3T-pretreated cells.
AGE-BSA signiﬁcantly increased protein carbonyl content
(P>0.0001 versus PBS and BSA controls). This trend was
not aﬀected by pretreatment with D3T (Figure 1(c)).
3.5. Inﬂuence of D3T on SH-SY5Y Cell Morphology. NAC
prevents AGE-induced neurite degeneration in SH-SY5Y
cells [36], so we tested whether increasing GSH with D3T
instead of NAC had the same protective eﬀect. We conﬁrmed
that AGE-BSA (4mg/mL for 24 hours) decreased the average
number of neurites per cell while the BSA control had no
eﬀect(Figure 1(d)).Consistentwithourpreviouswork,NAC
suppressed AGE-induced neurite degeneration. To assess the
inﬂuence of D3T on these outcomes, we pretreated cells with
50μM D3T and then followed with 24 hours of treatment
with 4mg/mL BSA, AGE-BSA, or equivalent dilution with
PBS.D3Thadnoindependenteﬀectsonneuritenumber,but
unlike NAC, D3T pretreatment did not protect the neurites
of SH-SY5Y cells treated with AGE-BSA. While both NAC
and D3T induced comparable GSH increases in SH-SY5Y
cells, albeit through separate mechanisms, NAC maintained
neurite number in cells exposed to AGE-BSA, and D3T
provided no protection.
3.6. Inﬂuence of D3T on ROS Formation. AGE-BSA caused
a signiﬁcant (P>0.0001 versus BSA control) increase in
ROS, an eﬀect abrogated by the NADPH oxidase-inhibitor
DPI and the PKC inhibitor rottlerin (Figure 2). We tested if
D3TpotentiatesAGE-inducedROSgeneration.Interestingly,
AGE-inducedROSlevelswerehigherafterD3Tpretreatment
than DMSO pretreatment (P>0.0001). This eﬀect was also
completely suppressed by DPI and rottlerin. Taken together,
thesedatasuggestthatthepotentiationofAGE-inducedROS
by D3T is speciﬁcally through the PKC-NADPH oxidase
pathway.
4. Discussion
Neuronal ROS generation in diabetes is increased by AGEs
[38], which induce superoxide radical production through a
pathway that connects RAGE and NADPH oxidase [39, 40].
Suppression of oxidative damage in diabetic neuropathy
models may provide insight into possible treatments for
this complication. Antioxidants like the green tea ﬂavonoid
EGCG [41]a sw e l la sα-lipoic acid, 17β-estradiol, and NAC
[27] protect neuroblastoma SH-SY5Y cells against AGE-
BSA.WepreviouslyreportedthatNACincreasesintracellular
GSH approximately threefold and suppresses the eﬀects of
AGEs on cell viability, neurite degeneration, and oxidative
damage [36], suggesting that the NAC-mediated mechanism
of protection is potent and deserving of further study.
Because NAC increases GSH by providing cysteine, the
limiting amino acid for GSH synthesis, we hypothesized that
ﬁnding alternative routes to increase intracellular GSH may
highlightothermechanismsforcytoprotectionagainstAGEs.
We tested if chemical induction of the endogenous
antioxidantsystem,whichincludesGSH,promotesSH-SY5Y
cell resistance to oxidative damage. We chose the compound
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Figure 1: D3T potentiates AGE-induced cytotoxicity. (a) SH-SY5Y cells were pretreated for 24 hours with 0–50μMD 3 Tf o l l o w e db ya2 4h r
treatmentwithBSAorAGE-BSA.MTTwasperformedasindicatedintheMaterialsandMethodssectionandabsorbanceswerestandardized
to 0.1% DMSO treatment. Results are from three independent experiments (n = 8–14); bar values are expressed as mean ± SD. (b) GSH
was measured by HPLC and standardized to total protein. Results are from four independent experiments (n = 4); bar values are expressed
as mean ± SD (∗P<0.01; ∗∗P<0.0005; ∗∗∗P<0.0001). (c) Cells were pretreated with 0.1% DMSO or 50μM D3T and then treated
with 4.0mg/mL BSA, AGE-BSA or an equivalent dilution of PBS. Protein oxidation was determined using an OxyBlot kit (Millipore). Band
intensity was quanitiﬁed by UN-SCAN-IT Gel 6.1 software (Silk Scientiﬁc, Orem, UT, USA) and standardized relative to PBS control with
DMSO pretreatment. Results are from three independent experiments; bar values are expressed as mean ± SD. (d) Cells were pretreated
with 0.1% DMSO- or 50μM D3T and then treated with 4.0mg/mL BSA, AGE-BSA ± 2.0mM NAC, or an equivalent dilution of PBS.
Neurite number was quantiﬁed using Image J software. Results are from three independent experiments (n = 3-4 random views); values are
expressed as mean ± SEM. Data were analyzed by ANOVA. Superscript letters that are not the same are signiﬁcantly diﬀerent (P<0.05).6 Experimental Diabetes Research
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Figure 2:D3TpotentiatesAGE-inducedROSgeneration.SH-SY5Y
c e l l sw e r ep r e t r e a t e df o r2 4h o u r sw i t hD M S Oo r5 0μMD 3 T .C e l l s
were treated with or without the NADPH oxidase inhibitor DPI
(20nM) or the PKC inhibitor rottlerin (2μM) for 30min and then
exposedto4mg/mLBSAorAGE-BSAfor16hours.ROSgeneration
is determined through DCF ﬂuorescence. Results are from three
independent experiments (n = 9). Bar values are expressed as
mean ± SD. Letters that are not the same are signiﬁcantly diﬀerent
(P<0.05).
independent negative eﬀects in SH-SY5Y cells in culture.
We found that D3T promoted cellular protection against
H2O2. Because AGE-induced oxidative damage is mediated
by H2O2 [27] and suppressed by GSH augmentation [36],
we hypothesized that D3T protects SH-SY5Y cells against
AGE-BSA. Surprisingly, D3T potentiated the cytotoxic and
GSH-depleting eﬀects of AGE-BSA. D3T had no inﬂuence
on neurite degeneration or protein carbonylation; further
consideration pointed to the possibility that worsening of
theseoutcomesmaynotbefeasibleinthismodel.Ourstudies
have not shown complete neurite degeneration, especially
during a relatively short timeframe like that in this study.
AGE-BSA exposure for 24 hours might have already caused
neuritedensitytodeclinetoitsrelativeminimum,preventing
D3T from causing further degeneration. Similarly, AGE-
BSA caused a substantial increase in protein carbonylation,
and this was not potentiated by D3T. AGE-induced protein
oxidation is robust and eﬀective, and conceivably, few
opportunities for carbonylation might remain. In all, the
antioxidant D3T is not protective against AGE-induced
oxidative damage in SH-SY5Y cells.
To test ROS generation in this model, we ﬁrst conﬁrmed
previous ﬁndings by Nitti et al., showing that AGEs induce
oxidative stress in a PKC and NADPH oxidase-dependent
manner[19].WefurtherdemonstratedthatD3Tpotentiated
AGE-induced ROS formation, which was suppressed by
inhibition of PKC and NADPH oxidase. This suggests that
D3T intensiﬁes AGE-induced oxidative stress by speciﬁcally
modulating the PKC-NADPH oxidase pathway. Nitti et
al. found similar trends for RA, which increases p47phox
expression and PKC activity in SH-SY5Y cells [19]a n d
increasescellularresponsivenesstoAGEs.Weaimtoperform
future studies to test if this mechanism is similar to that of
D3T.
In addition to D3T, our results showed that BSA also
increased intracellular GSH. These data are supportive of
the work by Cantin et al., demonstrating that albumin
increases intracellular GSH, likely due to its endocytosis,
degradation, and the utilization of its 34 cysteines [42]. Cells
can internalize glycated albumin [43], suggesting that the
GSH concentration diﬀerences between cells treated with
BSA and AGE-BSA is not due exclusively to diminished
biosynthesis. However, it is unclear if this process is aﬀected
by SH-SY5Y, so we will study this mechanism in our cells.
These ﬁndings are novel for a compound like D3T.
In another study, the green tea polyphenol EGCG, which
stimulates endogenous antioxidant defenses [44], was found
to potentiate the cytotoxic eﬀects of rotenone in SH-
SY5Y cells [45]. However, EGCG treatment independently
produced ROS in that study by Chung et al. This was
furtherevidencedasthecombinationofEGCGandrotenone
created a sum of ROS-producing mechanisms, resulting in
higher toxicity. Interestingly, D3T induces ROS formation
as part of its mechanism to increase antioxidant defenses
[46, 47]. Although we did not observe a signiﬁcant increase
in DCF ﬂuorescenceby D3T alone, wecannot yet exclude the
possibility that D3T subtly increases ROS in SH-SY5Y cells
and causes sensitivity to AGEs in a more general manner.
Chemical inducers of endogenous antioxidant defenses
are considered a potential therapeutic target for many
neurodegenerative diseases that have an oxidative stress
component. This includes diabetic neuropathy, for which
some studies show a protective role of these compounds.
However,manystudieshaveusedhighglucoseastheprimary
stressor in models of diabetic complications. Here, we used
AGEs and found that the compound D3T potentiates AGE-
induced oxidative damage. In the context of these ﬁndings,
it is imperative to study how D3T and similar compounds
aﬀect AGE-induced oxidative damage in additional cell and
animal models before phytochemical antioxidants can be
considered as useful in therapy for diabetic patients.
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